MARSEILLE, France, Jan. 18, 2008 - Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that it recently completed the enrollment of the first 90 patients in a Phase IIa clinical trial of its of lead product, TRO19622.
